Non-proportional hazards and applications in immuno-oncology

Non-proportional hazards and applications in immuno-oncology
Designs of clinical trials with time to event primary endpoints usually rely on hazards being constant over time. A major challenge in immuno-oncology is the delayed onset of benefit with such therapies and the presence of non-proportional hazards. The impact of this needs to be accounted for in sample size calculations, analysis methodology and reporting. At this meeting, we will examine possible strategies to handle such features, which may not be fully known when the trial is initiated.


4/1/2020 9:30 AM - 4:30 PM
Astra Zeneca/Medimmune Cambridge CB21 6GH. UNITED KINGDOM
This event is full.
All prices are in GBP.
If you are a PSI Non-Member and would like to register for an event, please use the link below to create an account. This is an account for events only and not a membership account.

Sign In